Skip to content

8-KAccepted Oct 26, 4:41 PM ET

Supernus Pharmaceuticals, Inc.: terminates UBS credit line

SUPERNUS PHARMACEUTICALS, INC.

Accepted (ET)

4:41 PM

Oct 26, 2026

Filed

Oct 26, 2026

Documents

11

Size

141.6 KB

Summary

Supernus Pharmaceuticals, Inc.: terminates UBS credit line

Updated

What happened The filing reports that on Oct 20, 2026, Supernus Pharmaceuticals, Inc. terminated the UBS Credit Line, dated Feb 8, 2023, between the company and UBS Bank USA. The filing states the UBS Credit Line was an uncommitted, demand revolving line of credit secured by a pledge of a securities collateral account. The termination was made "in anticipation of, and in connection with, the completion" of the company's previously announced business combination with Indivior Pharmaceuticals, Inc. under the Agreement and Plan of Merger dated Aug 1, 2026, and "in contemplation" of a new senior secured credit facility to be entered into by the combined company at closing.

Key details

  • UBS Credit Line dated Feb 8, 2023; terminated Oct 20, 2026.
  • As of termination, there were no advances, letters of credit, or other borrowings or obligations outstanding under the UBS Credit Line.
  • The company did not incur any early termination penalties in connection with the termination.
  • In connection with the termination, the Bank’s security interests in the collateral securing the UBS Credit Line were released.

Why it may matter This Form 8-K reports Item 1.02: termination of a material definitive agreement, which covers the termination of the UBS Credit Line and release of the related collateral and states the termination was tied to the announced merger with Indivior Pharmaceuticals, Inc. and planning for a new senior secured credit facility for the combined company. The filing does not show why the company acted.

AI-written summary · check the filing